Tina Parsons

This inventor holds 9 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignees: Cephalon Australia Pty. Ltd., Scancell Limited, Cancer Research Technology Limited. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tina Parsons. Retrieved from https://idiyas.com/inventor/tina-parsons

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 44.4

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 2.4

ph-index = 2

Forward Citations = 14(Granted Patents)

Company Filing History:

4 out of 9

Cephalon Australia Pty. Ltd.

Cancer Research Technology Limited

patents

4. 1 out of 104

University of Nottingham

patents

5. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12643956 - BINDING MEMBERS (2026-06-02),

2. 10835618 - Sialyl-di-Lewisas expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto (2020-11-17),

3. 10072073 - Glycans as functional cancer targets and antibodies thereto (2018-09-11),

4. 8343490 - Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent (2013-01-01),

5. 8273349 - Binding member which binds to both lewis-Y and lewis-B haptens, and its use for treating cancer (2012-09-25),

6. 8187600 - Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses (2012-05-29),

7. 7915387 - Monoclonal antibody Sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent (2011-03-29),

8. 7879983 - [object Object] (2011-02-01),

9. 7267821 - [object Object] (2007-09-11),

Title: Tina Parsons: Innovator in Cancer Research

Introduction

Tina Parsons is a prominent inventor based in Nottingham, GB. She has made significant contributions to the field of cancer research, holding a total of 9 patents. Her work focuses on innovative treatments and pharmaceutical compositions aimed at targeting cancer effectively.

Latest Patents

Among her latest patents is "Sialyl-di-Lewisas expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto." This invention relates to an isolated specific binding member capable of binding sialyl-di-Lewis, along with associated treatments and pharmaceutical compositions for cancer treatment. Another notable patent is "Glycans as functional cancer targets and antibodies thereto," which describes a glycan structure attached to a lipid or protein backbone, along with isolated binding members capable of binding to it.

Career Highlights

Tina has worked with notable companies in the industry, including Cephalon Australia Pty. Ltd. and Scancell Limited. Her experience in these organizations has allowed her to advance her research and contribute to the development of innovative cancer therapies.

Collaborations

Tina has collaborated with several professionals in her field, including Linda Gillian Durrant and Lindy Gillian Durrant. These collaborations have enriched her research and expanded her impact on cancer treatment.

Conclusion

Tina Parsons is a dedicated inventor whose work in cancer research has led to significant advancements in treatment options. Her innovative patents and collaborations highlight her commitment to improving healthcare outcomes for cancer patients.

Profile summary based on public USPTO records.